Brief: U.S. Food And Drug Administration Approves Orphan Drug Designation For Immix Biopharma Nxc-201 As A Treatment For Multiple Myeloma
23/08/2023 13:38
Aug 23 (Reuters) -
* U.S. FOOD AND DRUG ADMINISTRATION APPROVES ORPHAN DRUG
DESIGNATION FOR IMMIX BIOPHARMA NXC-201 AS A TREATMENT FOR
MULTIPLE MYELOMA
* IMMIX BIOPHARMA INC - FDA ORPHAN DRUG DESIGNATION ("ODD")
QUALIFIES NXC-201 FOR 7 YEARS OF U.S. MARKET EXCLUSIVITY AFTER
APPROVAL
* IMMIX BIOPHARMA INC - NXC-201 IS CURRENTLY BEING EVALUATED
IN A
PHASE 1B/2A CLINICAL TRIAL NEXICART-1
Source text for Eikon: ID:nGNX9JXh5s
Further company coverage: IMMX.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Immix Biopharma
See all newsBrief: Immix Biopharma Announces Closing Of $125 Million Underwritten Offering Of Common Stock
US RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
Brief: Immix Biopharma Announces Pricing Of $125 Million Underwritten Offering Of Common Stock
Brief: Immix Biopharma Announces 89% Complete Response Rate At Interim Update Across All Nexicart-2 Patients, With Mrd-Negativity Indicating Potential To Reach Up To 98% Complete Response Rate
Immix Biopharma, Inc. reports results for the quarter ended June 30 - Earnings Summary